Sino Biopharmaceutical’s Rovaxin tablets included in the breakthrough therapy program
August 9, 2025
Source: drugdu
68
On August 6, Sino Biopharmaceutical Co., Ltd. issued an announcement stating that the group's independently developed rovacitinib tablets "TQ05105 (JAK/ROCK inhibitor)" have been included in the Breakthrough Therapy Drug Program (BTD) by the Drug Review Center of the China National Medical Products Administration (CDE) for the treatment of chronic graft-versus-host disease (cGVHD).
This event indicates that the drug has significant advantages in treating chronic graft-versus-host disease and is expected to accelerate its approval and marketing. This will enhance the company's future performance expectations, strengthen investor confidence, and further enhance the company's competitiveness and valuation in the capital market.
https://finance.eastmoney.com/a/202508063477733776.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Zhengda Tianqing targets 9.2 billion yuan drug September 18, 2025
- Announcement on the Holding Subsidiary Obtaining Medical Device Registration Certificate September 18, 2025
- Plans to invest RMB 42.74 million in Wuhan Huajiyuan to advance clinical trials of the therapeutic antihypertensive vaccine (HJY-ATRQβ-001) project September 18, 2025
- Eli Lilly wins again! Oral weight loss drug outperforms oral sirolimus in head-to-head tria September 18, 2025
- Hengrui’s breakthrough hepatitis B therapy arrives September 17, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
